Conversations with experts about noteworthy topics in autism.
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.
Some conditions are too rare for conventional drug trials, leading some scientists to test bespoke treatments in single participants. Gleeson discusses the merits — and limitations — of these tiny trials.
Researchers know little about the ways genetic variants affect development in the infant brain. Knickmeyer, who launched the Organization for Imaging Genomics in Infancy, has spent the past five years trying to close the gap.
Countries across Latin America and the Caribbean struggle to collect data on autism, but Cecilia Montiel-Nava and the Latin American Autism Spectrum Network are beginning to change that.
The questionnaire, designed to screen children for autism, isn’t ready for clinical use without further validation, contrary to what some overblown newspaper headlines reported.
A new gene therapy approach for epilepsy tamps down neural activity on demand.
Psychiatric genomics promises to shed light on the genetic basis of autism, but it’s vital to include Africa in this research, Iyegbe and Okewole say.
Collecting brain scans from thousands of people can be challenging in autism research; data-sharing and collaborative efforts can help drive results that stand up to statistical scrutiny.
A new analysis package enables researchers to distill multiple measures of Angelman syndrome mice into a single ‘severity score.’
The pair’s new guidebook offers practical steps to make clinical trials easier and more meaningful for autistic participants.
